Article
Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion.
Biochemical pharmacology - 15 Dec 2003
Hacker Hans Jörg, Deres Karl, Mildenberger Maria, Schröder Claus H
Abstract excerpt
Recently, heteroarylpyrimidines (HAP) have been identified as potent inhibitors of capsid maturation. Here we discuss the HAP mode of action comparing the aggregation phenotype of wild-type and mutant core proteins with the respective phenotype imposed by HAP or other agents interacting with core protein. Pertinent tests include core fusion protein-mediated transactivation in a two-hybrid system and capsid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
